Exelixis (EXEL) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Aug, 2026Executive summary
Achieved Q2 2026 total revenues of $629 million, up 11% year-over-year, driven by strong cabozantinib (CABOMETYX) performance and collaboration revenues.
Net income for Q2 2026 was $212.1 million (GAAP), with diluted EPS of $0.82 and non-GAAP EPS of $0.91, both increasing from the prior year.
Advanced multi-franchise oncology strategy, with zanzalintinib NDA for third-line plus metastatic colorectal cancer under FDA review and launch preparations underway.
Continued investment in R&D and commercial infrastructure, with multiple pivotal trials for zanzalintinib and other pipeline assets ongoing or planned.
Completed significant stock repurchases, with new buyback programs authorized and strong liquidity maintained.
Financial highlights
Q2 2026 total revenues reached $629 million, with U.S. cabozantinib net product revenues of $573 million and global revenues of $806 million, up 10–13% year-over-year.
Collaboration revenues and royalties increased, driven by higher ex-U.S. sales and milestone achievements.
R&D expenses were $212 million, up from the prior year, mainly due to higher clinical trial and manufacturing costs.
SG&A expenses rose to $147.6 million, reflecting increased marketing, personnel, and stock-based compensation.
Cash and marketable securities totaled $1.38–$1.4 billion at quarter end.
Outlook and guidance
FY 2026 revenue guidance set at $2.50–$2.55 billion, with net product revenues of $2.30–$2.35 billion; guidance excludes potential U.S. zanzalintinib revenues.
R&D expense guidance lowered to $825–$875 million; SG&A guidance unchanged at $575–$625 million.
Full-year gross-to-net deductions projected at 30%–31%.
Latest events from Exelixis
- Zanza’s seven pivotal trials anchor a disciplined shift toward multiple franchises.EXEL
Jefferies Global Healthcare Conference - Zanzalintinib expansion and a 1Q RCC readout anchor the next growth phase.EXEL
UBS Global Biopharma Conference 2026 - Zanzalintinib’s 2027 milestones anchor a broader, multi-franchise growth strategy.EXEL
Stifel 2026 Healthcare Conference 2026 - CABO growth funds a broad zanza pipeline while R&D, BD and buybacks remain concurrent priorities.EXEL
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 10% as cabozantinib grew and zanzalintinib advanced; CRC review targets 2027.EXEL
Q3 2026 - Zanzalintinib’s pivotal pipeline and CRC launch plans anchor a multi-franchise growth strategy.EXEL
Morgan Stanley 24th Annual Global Healthcare Conference - Q4 revenue rose 13% as CABOMETYX expansion and pipeline growth shaped 2024 priorities.EXEL
Q4 2023 - CABOMETYX and zanzalintinib drive growth across oncology franchises, with AI boosting efficiency.EXEL
Citigroup’s Biopharma Back to School Summit 2026 - CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plans.EXEL
Wells Fargo 21st Annual Healthcare Conference